

Bing Xiong

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2287456/publications.pdf>

Version: 2024-02-01

101
papers

1,951
citations

279798

23
h-index

330143

37
g-index

111
all docs

111
docs citations

111
times ranked

2843
citing authors

#	ARTICLE	IF	CITATIONS
1	Discovery of 4-cyclopropyl-3-(2-((1-cyclopropyl-1H-pyrazol-4-yl) amino)) Tj ETQq1 1 0.784314 rgBT /Overlock 10 Tf 50 752 Td (quinazolinone) inhibitors for the treatment of idiopathic pulmonary fibrosis. <i>Acta Pharmaceutica Sinica B</i> , 2022, 12, 1943-1962.	12.0	4
2	Discovery of a novel DDRs kinase inhibitor XBLJ-13 for the treatment of idiopathic pulmonary fibrosis. <i>Acta Pharmacologica Sinica</i> , 2022, 43, 1769-1779.	6.1	7
3	Structure-Based Discovery of a Series of NSD2-PWWP1 Inhibitors. <i>Journal of Medicinal Chemistry</i> , 2022, 65, 9459-9477.	6.4	10
4	Design and development of a novel series of oral bivalent BET inhibitors with potent anticancer activities. <i>European Journal of Medicinal Chemistry</i> , 2022, 239, 114519.	5.5	4
5	Discovery of a series of 1H-pyrrolo[2,3-b]pyridine compounds as potent TNIK inhibitors. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2021, 33, 127749.	2.2	8
6	Structure of SARS-CoV-2 main protease in the apo state. <i>Science China Life Sciences</i> , 2021, 64, 656-659.	4.9	15
7	Phage-Display Based Discovery and Characterization of Peptide Ligands against WDR5. <i>Molecules</i> , 2021, 26, 1225.	3.8	4
8	Discovery of MTR-106 as a highly potent G-quadruplex stabilizer for treating BRCA-deficient cancers. <i>Investigational New Drugs</i> , 2021, 39, 1213-1221.	2.6	6
9	Allosteric Modulation: Dynamics is Double-Edged. <i>Journal of Medicinal Chemistry</i> , 2021, 64, 3694-3696.	6.4	2
10	Novel bivalent BET inhibitor N2817 exhibits potent anticancer activity and inhibits TAF1. <i>Biochemical Pharmacology</i> , 2021, 185, 114435.	4.4	8
11	Multi-omics characterization of WNT pathway reactivation to ameliorate BET inhibitor resistance in liver cancer cells. <i>Genomics</i> , 2021, 113, 1057-1069.	2.9	4
12	The Novel RET Inhibitor SYHA1815 Inhibits RET-Driven Cancers and Overcomes Gatekeeper Mutations by Inducing G1 Cell-Cycle Arrest through c-Myc Downregulation. <i>Molecular Cancer Therapeutics</i> , 2021, 20, 2198-2206.	4.1	6
13	Divalent tranilcypromine derivative as lysine-specific demethylase 1 inhibitor. <i>Medicinal Chemistry Research</i> , 2021, 30, 421-428.	2.4	1
14	Structure-Based Discovery of Potent CARM1 Inhibitors for Solid Tumor and Cancer Immunology Therapy. <i>Journal of Medicinal Chemistry</i> , 2021, 64, 16650-16674.	6.4	15
15	A new BET inhibitor, 171, inhibits tumor growth through cell proliferation inhibition more than apoptosis induction. <i>Investigational New Drugs</i> , 2020, 38, 700-713.	2.6	4
16	EPHA2 feedback activation limits the response to PDE1 γ inhibition in KRAS-dependent cancer cells. <i>Acta Pharmacologica Sinica</i> , 2020, 41, 270-277.	6.1	4
17	Rational Design and Evaluation of 6-(Pyrimidin-2-ylamino)-3,4-dihydroquinoxalin-2(1 <i>H</i>)-ones as Polypharmacological Inhibitors of BET and Kinases. <i>Journal of Medicinal Chemistry</i> , 2020, 63, 9787-9802.	6.4	12
18	Inhibition of the BET family reduces its new target gene IDO1 expression and the production of l-kynurenine. <i>Cell Death and Disease</i> , 2019, 10, 557.	6.3	14

#	ARTICLE	IF	CITATIONS
19	Structure-Based Discovery and Development of a Series of Potent and Selective Bromodomain and Extra-Terminal Protein Inhibitors. <i>Journal of Medicinal Chemistry</i> , 2019, 62, 8642-8663.	6.4	30
20	Design and Synthesis of Potent, Selective Inhibitors of Protein Arginine Methyltransferase 4 against Acute Myeloid Leukemia. <i>Journal of Medicinal Chemistry</i> , 2019, 62, 5414-5433.	6.4	13
21	Discovery and optimization of a series of 3-substituted indazole derivatives as multi-target kinase inhibitors for the treatment of lung squamous cell carcinoma. <i>European Journal of Medicinal Chemistry</i> , 2019, 163, 671-689.	5.5	12
22	Fragment-based drug discovery of triazole inhibitors to block PDE β -RAS protein-protein interaction. <i>European Journal of Medicinal Chemistry</i> , 2019, 163, 597-609.	5.5	20
23	Discovery of a series of dimethoxybenzene FGFR inhibitors with 5H-pyrrolo[2,3-b]pyrazine scaffold: structure-activity relationship, crystal structural characterization and in vivo study. <i>Acta Pharmaceutica Sinica B</i> , 2019, 9, 351-368.	12.0	5
24	Tranylcypromine and 6-trifluoroethyl thienopyrimidine hybrid as LSD1 inhibitor. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2019, 29, 844-847.	2.2	10
25	Stereoselective N-glycosylation with N4-acyl cytosines and efficient synthesis of gemcitabine. <i>Tetrahedron</i> , 2019, 75, 1203-1213.	1.9	2
26	Structure-based optimization of a series of selective BET inhibitors containing aniline or indoline groups. <i>European Journal of Medicinal Chemistry</i> , 2018, 150, 156-175.	5.5	16
27	Convenient preparation of pinometostat and related 5 β -deoxy-5 β -amino adenosine derivatives as well as their activity against DOT1L. <i>Tetrahedron Letters</i> , 2018, 59, 415-417.	1.4	1
28	Preclinical Evaluation of SCC244 (Glumetinib), a Novel, Potent, and Highly Selective Inhibitor of c-Met in MET-dependent Cancer Models. <i>Molecular Cancer Therapeutics</i> , 2018, 17, 751-762.	4.1	22
29	Fragment-Based Drug Discovery for Developing Inhibitors of Protein-Protein Interactions. , 2018, , 135-176.		0
30	Structure-Based Discovery of a Series of 5H-Pyrrolo[2,3-b]pyrazine FGFR Kinase Inhibitors. <i>Molecules</i> , 2018, 23, 698.	3.8	11
31	Efficient syntheses of alpha- and beta-C-nucleosides and the origin of anomeric selectivity. <i>Organic Chemistry Frontiers</i> , 2018, 5, 1992-1999.	4.5	5
32	Design and optimization of purine derivatives as in vivo active PDE10A inhibitors. <i>Bioorganic and Medicinal Chemistry</i> , 2017, 25, 3315-3329.	3.0	7
33	Discovery of a series of dihydroquinoxalin-2(1H)-ones as selective BET inhibitors from a dual PLK1-BRD4 inhibitor. <i>European Journal of Medicinal Chemistry</i> , 2017, 137, 176-195.	5.5	28
34	Stereoselective addition of Grignard reagents to (2-methyl-5-tert-butyl)phenyl 1-thio- β -D-ribose-2,3,4-tri-O-acetyl-1,4-furanoside derivative. <i>Tetrahedron</i> , 2017, 73, 2290-2304.	1.9	4
35	A one-pot synthesis of omarigliptin and its analogues through stabilized beta-amino ketone intermediate. <i>Synthetic Communications</i> , 2017, 47, 357-363.	2.1	0
36	Preparation of 5 β -deoxy-5 β -amino-5 β -C-methyl adenosine derivatives and their activity against DOT1L. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2017, 27, 4960-4963.	2.2	8

#	ARTICLE	IF	CITATIONS
37	Discovery and Biological Evaluation of a Series of Pyrrolo[2,3-b]pyrazines as Novel FGFR Inhibitors. <i>Molecules</i> , 2017, 22, 583.	3.8	8
38	Novel PARP1/2 inhibitor mefuparib hydrochloride elicits potent <i>in vitro</i> and <i>in vivo</i> anticancer activity, characteristic of high tissue distribution. <i>Oncotarget</i> , 2017, 8, 4156-4168.	1.8	31
39	Design, Synthesis and Biological Evaluation of 6-(2,6-Dichloro-3,5-dimethoxyphenyl)-4-substituted-1H-indazoles as Potent Fibroblast Growth Factor Receptor Inhibitors. <i>Molecules</i> , 2016, 21, 1407.	3.8	10
40	Discovery of a new series of imidazo[1,2-a]pyridine compounds as selective c-Met inhibitors. <i>Acta Pharmacologica Sinica</i> , 2016, 37, 698-707.	6.1	22
41	Formation of 1,3-diazocine by palladium catalyzed C-H arylation. <i>Tetrahedron Letters</i> , 2016, 57, 2311-2314.	1.4	7
42	Design and synthesis of benzylpiperidine inhibitors targeting the menin-MLL1 interface. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2016, 26, 4472-4476.	2.2	9
43	Targeting Hsp90 with FS-108 circumvents gefitinib resistance in EGFR mutant non-small cell lung cancer cells. <i>Acta Pharmacologica Sinica</i> , 2016, 37, 1587-1596.	6.1	4
44	Stereoselective and Regioselective Preparation of C-Pentopyranosides and Formal Synthesis of Omarigliptin. <i>European Journal of Organic Chemistry</i> , 2016, 2016, 5624-5628.	2.4	3
45	NMR-based platform for fragment-based lead discovery used in screening BRD4-targeted compounds. <i>Acta Pharmacologica Sinica</i> , 2016, 37, 984-993.	6.1	17
46	Tetrahydroisoquinolines as novel histone deacetylase inhibitors for treatment of cancer. <i>Acta Pharmaceutica Sinica B</i> , 2016, 6, 93-99.	12.0	18
47	Design and discovery of new pyrimidine coupled nitrogen aromatic rings as chelating groups of JMJD3 inhibitors. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2016, 26, 721-725.	2.2	17
48	Design and Optimization of a Series of 1-Sulfonylpyrazolo[4,3-b]pyridines as Selective c-Met Inhibitors. <i>Journal of Medicinal Chemistry</i> , 2015, 58, 2513-2529.	6.4	42
49	Fragment-Based Drug Discovery of 2-Thiazolidinones as BRD4 Inhibitors: 2. Structure-Based Optimization. <i>Journal of Medicinal Chemistry</i> , 2015, 58, 1281-1297.	6.4	50
50	Multi-substituted 8-aminoimidazo[1,2-a]pyrazines by Groebke-Blackburn-Bienaymé reaction and their Hsp90 inhibitory activity. <i>Organic and Biomolecular Chemistry</i> , 2015, 13, 1531-1535.	2.8	20
51	FS-93, an Hsp90 inhibitor, induces G2/M arrest and apoptosis via the degradation of client proteins in oncogene addicted and derived resistant cancer cells. <i>Oncoscience</i> , 2015, 2, 419-427.	2.2	6
52	Direct Glycosylation of Bioactive Small Molecules with Glycosyl Iodide and Strained Olefin as Acid Scavenger. <i>Journal of Organic Chemistry</i> , 2014, 79, 1100-1110.	3.2	24
53	Strained olefin enables triflic anhydride mediated direct dehydrative glycosylation. <i>Organic and Biomolecular Chemistry</i> , 2014, 12, 9781-9785.	2.8	19
54	Condensed Fukui function predicts innate C-H radical functionalization sites on multi-nitrogen containing fused arenes. <i>RSC Advances</i> , 2014, 4, 17262-17264.	3.6	35

#	ARTICLE	IF	CITATIONS
55	Discovery of potent N-(isoxazol-5-yl)amides as HSP90 inhibitors. <i>European Journal of Medicinal Chemistry</i> , 2014, 87, 765-781.	5.5	33
56	Highly Stereoselective Nucleophilic Addition of Difluoromethyl-2-pyridyl Sulfone to Sugar Lactones and Efficient Synthesis of Fluorinated 2-Ketoses. <i>European Journal of Organic Chemistry</i> , 2014, 2014, 6150-6154.	2.4	16
57	Mechanism of the All- $\hat{1}$ to All- $\hat{2}$ Conformational Transition of RfaH-CTD: Molecular Dynamics Simulation and Markov State Model. <i>Journal of Chemical Theory and Computation</i> , 2014, 10, 2255-2264.	5.3	37
58	1,2-trans-1-Dihydroxyboryl benzyl S-glycoside as glycosyl donor. <i>Carbohydrate Research</i> , 2014, 398, 45-49.	2.3	8
59	Identification of a new series of potent diphenol HSP90 inhibitors by fragment merging and structure-based optimization. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2014, 24, 2525-2529.	2.2	16
60	Discovery of pyrazole as C-terminus of selective BACE1 inhibitors. <i>European Journal of Medicinal Chemistry</i> , 2013, 68, 270-283.	5.5	20
61	Virtual Screening and Structure-Based Discovery of Indole Acylguanidines as Potent $\hat{2}$ -secretase (BACE1) Inhibitors. <i>Molecules</i> , 2013, 18, 5706-5722.	3.8	24
62	Design, synthesis and SAR of piperidyl-oxadiazoles as $\hat{11}$ -hydroxysteroid dehydrogenase 1 inhibitors. <i>European Journal of Medicinal Chemistry</i> , 2013, 62, 1-10.	5.5	13
63	Water PMF for predicting the properties of water molecules in protein binding site. <i>Journal of Computational Chemistry</i> , 2013, 34, 583-592.	3.3	25
64	Design and Synthesis of Arylsulfonylpiperidine-carboxamides as $\hat{11}$ -Hydroxysteroid Dehydrogenase Type 1 Inhibitors. <i>ChemMedChem</i> , 2013, 8, 577-581.	3.2	6
65	Design and Synthesis of (2,4,5-Trifluorophenyl)butane-diamines as Dipeptidyl Peptidase-IV Inhibitors. <i>ChemMedChem</i> , 2013, 8, 1104-1116.	3.2	10
66	Fragment-Based Drug Discovery of 2-Thiazolidinones as Inhibitors of the Histone Reader BRD4 Bromodomain. <i>Journal of Medicinal Chemistry</i> , 2013, 56, 3833-3851.	6.4	113
67	Energetic factors determining the binding of type I inhibitors to c-Met kinase: experimental studies and quantum mechanical calculations. <i>Acta Pharmacologica Sinica</i> , 2013, 34, 1475-1483.	6.1	5
68	Structural Analysis of a Novel Cyclohexylamine Oxidase from <i>Brevibacterium oxydans</i> IH-35A. <i>PLoS ONE</i> , 2013, 8, e60072.	2.5	22
69	Back Cover: Discovery of 3H-Imidazo[4,5-b]pyridines as Potent c-Met Kinase Inhibitors: Design, Synthesis, and Biological Evaluation (<i>ChemMedChem</i> 6/2012). <i>ChemMedChem</i> , 2012, 7, 1129-1129.	3.2	0
70	Discovery of 2-Alkyl-1-arylsulfonylprolinamides as $\hat{11}$ -Hydroxysteroid Dehydrogenase Type 1 Inhibitors. <i>ACS Medicinal Chemistry Letters</i> , 2012, 3, 793-798.	2.8	11
71	CCLab—a multi-objective genetic algorithm based combinatorial library design software and an application for histone deacetylase inhibitor design. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2012, 22, 4540-4545.	2.2	13
72	Discovery of 3H-imidazo[4,5-b]pyridines as Potent c-Met Kinase Inhibitors: Design, Synthesis, and Biological Evaluation. <i>ChemMedChem</i> , 2012, 7, 1057-1070.	3.2	12

#	ARTICLE	IF	CITATIONS
73	Discovery of novel sulfonamides as potent and selective inhibitors against human and mouse 11 β -hydroxysteroid dehydrogenase type 1. <i>Molecular and Cellular Endocrinology</i> , 2012, 358, 46-52.	3.2	12
74	Knowledge-Based Scoring Functions in Drug Design: 2. Can the Knowledge Base Be Enriched?. <i>Journal of Chemical Information and Modeling</i> , 2011, 51, 386-397.	5.4	31
75	Knowledge-Based Scoring Functions in Drug Design: 3. A Two-Dimensional Knowledge-Based Hydrogen-Bonding Potential for the Prediction of Protein-Ligand Interactions. <i>Journal of Chemical Information and Modeling</i> , 2011, 51, 2994-3004.	5.4	17
76	Potent and novel 11 β -HSD1 inhibitors identified from shape and docking based virtual screening. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2011, 21, 5739-5744.	2.2	14
77	MT119, a new planar-structured compound, targets the colchicine site of tubulin arresting mitosis and inhibiting tumor cell proliferation. <i>International Journal of Cancer</i> , 2011, 129, 214-224.	5.1	24
78	Sulfated polymannuroguluronate inhibits Tat-induced SLK cell adhesion via a novel binding site, a KKR spatial triad. <i>Acta Pharmacologica Sinica</i> , 2011, 32, 647-654.	6.1	9
79	Crystal Structures of Two Aminoglycoside Kinases Bound with a Eukaryotic Protein Kinase Inhibitor. <i>PLoS ONE</i> , 2011, 6, e19589.	2.5	23
80	Discovery of benzhydrylpiperazine derivatives as CB1 receptor inverse agonists via privileged structure-based approach. <i>European Journal of Medicinal Chemistry</i> , 2010, 45, 1133-1139.	5.5	15
81	Aromatic β -amino-ketone derivatives as novel selective non-steroidal progesterone receptor antagonists. <i>Bioorganic and Medicinal Chemistry</i> , 2010, 18, 4255-4268.	3.0	12
82	MT7, a novel compound from a combinatorial library, arrests mitosis via inhibiting the polymerization of microtubules. <i>Investigational New Drugs</i> , 2010, 28, 715-728.	2.6	22
83	BSSF: a fingerprint based ultrafast binding site similarity search and function analysis server. <i>BMC Bioinformatics</i> , 2010, 11, 47.	2.6	27
84	Structure of the Antibiotic Resistance Factor Spectinomycin Phosphotransferase from <i>Legionella pneumophila</i> . <i>Journal of Biological Chemistry</i> , 2010, 285, 9545-9555.	3.4	36
85	Knowledge-Based Scoring Functions in Drug Design. 1. Developing a Target-Specific Method for Kinase-Ligand Interactions. <i>Journal of Chemical Information and Modeling</i> , 2010, 50, 1378-1386.	5.4	33
86	Dopamine D ₁ receptor ligands: Where are we now and where are we going. <i>Medicinal Research Reviews</i> , 2009, 29, 272-294.	10.5	117
87	ScafBank: a public comprehensive Scaffold database to support molecular hopping. <i>Acta Pharmacologica Sinica</i> , 2009, 30, 251-258.	6.1	19
88	Discovery of potent β -secretase (bace-1) inhibitors by the synthesis of isophthalamide-containing hybrids. <i>Acta Pharmacologica Sinica</i> , 2009, 30, 259-269.	6.1	6
89	Design, synthesis and biological evaluation of novel dual inhibitors of acetylcholinesterase and β -secretase. <i>Bioorganic and Medicinal Chemistry</i> , 2009, 17, 1600-1613.	3.0	95
90	The type IA topoisomerase catalytic cycle: A normal mode analysis and molecular dynamics simulation. <i>Proteins: Structure, Function and Bioinformatics</i> , 2008, 71, 1984-1994.	2.6	12

#	ARTICLE	IF	CITATIONS
91	Illudalic acid as a potential LAR inhibitor: Synthesis, SAR, and preliminary studies on the mechanism of action. <i>Bioorganic and Medicinal Chemistry</i> , 2008, 16, 7399-7409.	3.0	23
92	DrugViz: a Cytoscape plugin for visualizing and analyzing small molecule drugs in biological networks. <i>Bioinformatics</i> , 2008, 24, 2117-2118.	4.1	14
93	Conserved $\hat{\pm}$ -Helix Acts as Autoinhibitory Sequence in AMP-activated Protein Kinase $\hat{\pm}$ Subunits. <i>Journal of Biological Chemistry</i> , 2007, 282, 495-506.	3.4	96
94	Quinoxalinyurea derivatives as a novel class of JSP-1 inhibitors. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2007, 17, 2118-2122.	2.2	14
95	Design, synthesis and antitumor evaluation of a new series of N-substituted-thiourea derivatives. <i>Acta Pharmacologica Sinica</i> , 2006, 27, 1259-1271.	6.1	26
96	Construction of a small peptide library related to inhibitor OM99-2 and its structure-activity relationship to γ -secretase. <i>Acta Pharmacologica Sinica</i> , 2006, 27, 1586-1593.	6.1	10
97	Salvicine Functions as Novel Topoisomerase II Poison by Binding to ATP Pocket. <i>Molecular Pharmacology</i> , 2006, 70, 1593-1601.	2.3	54
98	Structures of aminoglycoside acetyltransferase AAC(6 $\hat{\epsilon}$)-II in a novel crystal form: structural and normal-mode analyses. <i>Acta Crystallographica Section D: Biological Crystallography</i> , 2005, 61, 1273-1279.	2.5	23
99	Crystallization and preliminary crystallographic analysis of an aminoglycoside kinase from <i>Legionella pneumophila</i> . <i>Acta Crystallographica Section F: Structural Biology Communications</i> , 2005, 61, 606-608.	0.7	4
100	Inhibitory Mode of 1,5-Diarylpyrazole Derivatives against Cyclooxygenase-2 and Cyclooxygenase-1: $\hat{\text{A}}$ Molecular Docking and 3D QSAR Analyses. <i>Journal of Medicinal Chemistry</i> , 2002, 45, 4816-4827.	6.4	61
101	Brownian Dynamics Simulations of the Recognition of the Scorpion Toxin Maurotoxin with the Voltage-Gated Potassium Ion Channels. <i>Biophysical Journal</i> , 2002, 83, 2370-2385.	0.5	49